What’s Health Canada Saying about Biosimilars?

CDHF

Written by: CDHF

Updated: November 9th, 2022

A biosimilar biologic drug, or biosimilar, is a drug demonstrated to be highly similar to a biologic drug that was already authorized for sale (known as the reference biologic drug).  Biosimilars are approved based on a thorough comparison to a reference drug and may enter the market after the expiry of reference drug patents and data protection. Watch this video to get more insight into what Health Canada is saying about biosimilars! Learn more about biosimilars here.

Related Articles:

View all News & Articles

Test tubes of a drug

Switching from a Biologic to a Biosimilar Drug in Canada

Two cartoon medicine bottles on white background

Saskatchewan Biosimilars Initiative

Biosimilars Initiatives Banner

Biosimilars Initiatives

British Columbia Flag marking a map of Canada

BC Biosimilars Initiative: Phase Two Information

Map of Alberta close up

Alberta Health Biosimilars Initiative

Two cartoon medicine bottles on white background

Nova Scotia Biosimilar Initiative

CDHF Talks: Dietary Updates and Recommendations for the IBD Patient on a Biosimilar

Two cartoon medicine bottles on white background

Quebec Biosimilars Initiative

Flag of New Brunswick on a pin stuck on a map showing New Brunswick

New Brunswick Biosimilars Initiative

IBD Animation

Switching from a Biologic to a Biosimilar

What’s Health Canada Saying about Biosimilars?

Teen boy talking to doctor

Biosimilars for IBD: Making the Transition Webinar

CDHF Talks: Your New Infusion Clinic